Global Health Institute

The Global Health Institute of Merck KGaA, Darmstadt, Germany is mandated to improve the health of underserved populations in the developing world addressing unmet medical needs related to infectious diseases.


Our Vision

In line with our corporate responsibility, the company is committed to improving the health of underserved populations that lack access to health solutions including prevention, diagnostics and therapy.
Through science and technology innovation, the Institute is mandated to impact in a sustainable manner to the worldwide Global Health Agenda for the Company by strengthening control of infectious diseases as well as contributing to elimination agendas.

Our Goal

The Institute is working to address key unmet medical needs related to infectious diseases such as schistosomiasis and malaria as well as bacterial infections and related antimicrobial resistance.
The goal is to develop and provide access to transformative and integrated innovations for the most vulnerable populations (children and women) suffering from schistosomiasis, malaria and bacterial infections, in developing countries.

Our approach

The Global Health Institute defines and implements an integrated strategy to develop and deliver health solutions that address major global health challenges.

The approach covers:

  • Treatments for high unmet medical needs
  • Detection focusing on highly sensitive and specific diagnostic methods
  • Transmission controls for developing products and technologies to improve preventive measures
  • Methods & tools to strengthen health systems through technologies and education programs.

Our operating model

The Global Health Institute operates through a social business model that aims to ensure sustainability, affordability and availability of final products and services.
It consists of a non-maximizing profit model to increase impact and ensuring financial sustainability.
The Institute also applies the shared value concept which combines its focus on both societal and economic progress.

The model is based on public-private partnerships with leading global health institutions/organizations in both developed and developing countries.

Our portfolio

The Institute has built up, broadened and advanced a comprehensive portfolio, including the following programs:

  • Development of a pediatric Praziquantel (PZQ) formulation to treat schistosomiasis in children under the age of six
    More information 
  • Development of a new active ingredient for the treatment and prevention of malaria in very young children
  • Screening programs through dedicated drug discovery platforms for new potential candidates against schistosomiasis and malaria
  • Development of diagnostics for schistosomiasis and for malaria
  • Development of products and technologies to improve preventive measures

The Institute’s structure, integrated strategy and operating model as well as its portfolio showcases the Company’s continuous engagement in the fight against infectious diseases, to improve health for all.
The Access to Medicines Index 2018 report published in November 2018 highlights the Institute as a leading practice to accelerate R&D, incorporate access provisions and build capacity for projects and initiatives targeting schistosomiasis, malaria and other infections.

Global Health Institute (Merck KGaA, Darmstadt, Germany)
More information
Global Health Institute (Merck KGaA, Darmstadt, Germany)

The Institute develops and provides access to integrated health solutions for children and women to address major global health challenges..

Consortium Pediatric Praziquantel Program
More information
Consortium Pediatric Praziquantel Program

The Pediatric Praziquantel Consortium is an international public-private partnership that aims to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children (below 6 years of age).

The Integrated Malaria Program
More information
The Integrated Malaria Program

Effective control of malaria requires an integrated approach. The Malaria program aims to develop treatments, diagnostics as well as vector control methods; it also seeks to strengthen health systems through research initiatives and educational programs in and for developing countries.

Our Contact

The Global Health team can be contacted at:  GlobalHealth@emdgroup.com

Please visit the Institute’s website for more information at: www.emdglobalhealthinstitute.com

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement